Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

15.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
15.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.5K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.5K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.2K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.2K
EDTA: Chemistry and Properties01:22

EDTA: Chemistry and Properties

2.4K
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...
2.4K
Metal-Ligand Bonds02:51

Metal-Ligand Bonds

22.4K
The hemoglobin in the blood, the chlorophyll in green plants, vitamin B-12, and the catalyst used in the manufacture of polyethylene all contain coordination compounds. Ions of the metals, especially the transition metals, are likely to form complexes.
In these complexes, transition metals form coordinate covalent bonds, a kind of Lewis acid-base interaction in which both of the electrons in the bond are contributed by a donor (Lewis base) to an electron acceptor (Lewis acid). The Lewis acid in...
22.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noble Metal Complexes and Non-Canonical Nucleic Acids: From G-Quadruplex Recognition to Emerging Functional Architectures.

Biomolecules·2026
Same author

The Reactivity of Diiron(I) Bis-cyclopentadienyl Tricarbonyl Aminocarbyne Complexes in Aqueous Media: A Case Study for Iron-Based Anticancer Agents.

Inorganic chemistry·2026
Same author

Selective Functionalization with Organophosphite Ligands of Atomically Precise Platinum Chini Clusters.

Inorganic chemistry·2026
Same author

Engineering oxaliplatin(IV) prodrugs with monohaloacetates for redox-responsive and multimodal anticancer activity.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Diiron(I) Bis(cyclopentadienyl) Complexes with Bridging Iminium Ligands: From Foundational Organometallic Chemistry to Unique Reactivity and Biological Potential.

Accounts of chemical research·2026
Same author

Isocyanide Incorporation Expands the Anticancer Potential of Diiron(I) Aminocarbyne Complexes.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Related Experiment Video

Updated: Oct 22, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

58.1K

Anticancer Diiron Vinyliminium Complexes: A Structure-Activity Relationship Study.

Simona Braccini1, Giorgia Rizzi1, Lorenzo Biancalana1

  • 1Department of Chemistry and Industrial Chemistry, University of Pisa, Via G. Moruzzi 13, I-56124 Pisa, Italy.

Pharmaceutics
|August 28, 2021
PubMed
Summary
This summary is machine-generated.

New diiron complexes show potent and selective cytotoxicity against cancer cells. These compounds also demonstrate potential in inhibiting thioredoxin reductase, suggesting a promising new avenue for cancer therapy.

Keywords:
ROS productioncytotoxicitydiiron complexesmetal-based drugsthioredoxin reductase inhibition

More Related Videos

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

648
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.1K

Related Experiment Videos

Last Updated: Oct 22, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

58.1K
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

648
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

14.1K

Area of Science:

  • Organometallic Chemistry
  • Medicinal Chemistry
  • Biochemistry

Background:

  • Diiron complexes are of interest due to their diverse reactivity and potential biological applications.
  • Developing novel metal-based anticancer agents with improved selectivity and reduced toxicity is a critical area of research.

Purpose of the Study:

  • To synthesize and characterize a series of novel diiron complexes with varying substituents on a bridging vinyliminium ligand.
  • To evaluate the cytotoxicity, selectivity, and mechanism of action of these complexes against cancer cell lines.

Main Methods:

  • Synthesis of diiron complexes via reactions of diiron μ-aminocarbyne precursors with alkynes.
  • Characterization using elemental analysis, IR, NMR, and X-ray diffraction.
  • Assessment of aqueous solubility, stability, and lipophilicity using NMR and UV-Vis spectroscopy.
  • Cytotoxicity screening against A2780 and Balb/3T3 cell lines, and antiproliferative assays on cisplatin-resistant A2780cisR cells.
  • Investigation of reactive oxygen species (ROS) production, cytochrome c interaction, and thioredoxin reductase (TrxR) inhibition via ESI-MS.

Main Results:

  • Sixteen novel diiron complexes were synthesized in high yields.
  • Complexes exhibited potent and selective cytotoxicity against the A2780 cancer cell line compared to nontumoral cells.
  • The most potent complex, 4c, showed significant antiproliferative activity.
  • Selected complexes induced significant ROS production in cancer cells.
  • Complexes did not interact with cytochrome c but showed potential for TrxR inhibition.

Conclusions:

  • The synthesized diiron complexes represent a promising class of anticancer agents with high selectivity.
  • Their ability to induce ROS and inhibit TrxR suggests a multifaceted mechanism of action.
  • Further investigation into these complexes could lead to the development of novel cancer therapeutics.